Skip to content
zameds

Paracetamol, phenylephrine, sodium citrate (Lemsip)

Paracetamol, phenylephrine, sodium citrate

Reckitt Benckinser Pharmaceuticals (Pty) Ltd

Every registration of this product has been cancelled.

Registration

Applicant
Reckitt Benckinser Pharmaceuticals (Pty) Ltd
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Lemsip

EACH 4,075 g CONTAINS PARACETAMOL 650 MG PHENYLEPHRINE HYDROCHLORIDE 5 MG SODIUM CITRATE 500 MG

Not listedB0032B/5.8/32CancelledNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Phenylephrine

    • when intended for injection
    • except ophthalmic preparations containing 0,2 percent or less. (S0)
    • except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)

    Consolidated Schedules 06 July 2026, lines 7545 to 7552

  • S3: Paracetamol

    • when intended for injection.

    Consolidated Schedules 06 July 2026, line 4093

  • S2: Paracetamol

    • when contained in rectal suppositories, or
    • when contained in modified release formulations. (S0, S1, S3)

    Consolidated Schedules 06 July 2026, lines 2496 to 2500

  • S1: Paracetamol

    • immediate release tablets or capsules each containing 500 milligrams or less of paracetamol, or in individually wrapped powders or in sachets containing 1 000 milligrams or less of paracetamol, subject to - (i) a maximum of 12,5 grams of paracetamol per primary pack, and (ii) in the case of tablets or capsules, presented in blister strip packaging or in containers with child-resistant closures; and (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
    • in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres or in paediatric drops containing 120 milligrams or less of paracetamol per 1,2 millilitres, subject to - (i) a maximum of 100 millilitres per primary pack in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres; (ii) a maximum of 20 millilitres per primary pack in the case of the paediatric drops; (iii) labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton): “CONTAINS PARACETAMOL - READ THE PACKAGE INSERT”; (S0)
    • when contained in rectal suppositories. (S2)
    • when contained in modified release formulations. (S2)
    • when intended for injection. (S3)

    Consolidated Schedules 06 July 2026, lines 958 to 997

  • S1: Phenylephrine

    • when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent; (S1)
    • except ophthalmic preparations containing 0,2 percent or less; (S0)
    • except when intended for injection. (S4)

    Consolidated Schedules 06 July 2026, lines 1007 to 1014

14 of 67 approved products with this ingredient carry S5 on their leaflet.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Combination product

This product contains more than one active ingredient, so it has no single molecular structure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles